368,305 Shares in Xencor, Inc. $XNCR Bought by Seven Fleet Capital Management LP

Seven Fleet Capital Management LP purchased a new stake in shares of Xencor, Inc. (NASDAQ:XNCR - Free Report) during the 2nd quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm purchased 368,305 shares of the biopharmaceutical company's stock, valued at approximately $7,828,524,000. Xencor accounts for 1.3% of Seven Fleet Capital Management LP's holdings, making the stock its 17th biggest position. Seven Fleet Capital Management LP owned approximately 0.50% of Xencor at the end of the most recent reporting period.

A number of other large investors have also modified their holdings of XNCR. ProShare Advisors LLC grew its position in shares of Xencor by 6.5% during the 4th quarter. ProShare Advisors LLC now owns 16,853 shares of the biopharmaceutical company's stock valued at $258,000 after acquiring an additional 1,026 shares during the period. Cerity Partners LLC boosted its position in Xencor by 3.8% during the fourth quarter. Cerity Partners LLC now owns 31,302 shares of the biopharmaceutical company's stock worth $479,000 after purchasing an additional 1,143 shares in the last quarter. State of Tennessee Department of Treasury grew its holdings in Xencor by 6.2% in the second quarter. State of Tennessee Department of Treasury now owns 30,721 shares of the biopharmaceutical company's stock valued at $241,000 after purchasing an additional 1,784 shares during the period. CANADA LIFE ASSURANCE Co increased its position in shares of Xencor by 3.3% in the second quarter. CANADA LIFE ASSURANCE Co now owns 70,015 shares of the biopharmaceutical company's stock valued at $550,000 after buying an additional 2,256 shares in the last quarter. Finally, Tower Research Capital LLC TRC raised its stake in shares of Xencor by 118.4% during the 2nd quarter. Tower Research Capital LLC TRC now owns 5,568 shares of the biopharmaceutical company's stock worth $44,000 after buying an additional 3,018 shares during the period.

Analysts Set New Price Targets

A number of research firms recently issued reports on XNCR. Zacks Research raised shares of Xencor from a "strong sell" rating to a "hold" rating in a research note on Monday, July 6th. Wedbush upped their price objective on shares of Xencor from $26.00 to $30.00 and gave the stock an "outperform" rating in a research report on Thursday, August 6th. Weiss Ratings restated a "sell (d-)" rating on shares of Xencor in a research report on Wednesday, June 24th. JPMorgan Chase & Co. increased their price objective on shares of Xencor from $13.00 to $14.00 and gave the company a "neutral" rating in a report on Monday, May 11th. Finally, Cantor Fitzgerald lifted their target price on shares of Xencor from $43.00 to $44.00 and gave the company an "overweight" rating in a research report on Thursday, August 6th. Five investment analysts have rated the stock with a Buy rating, three have issued a Hold rating and one has issued a Sell rating to the company. According to MarketBeat.com, Xencor has a consensus rating of "Hold" and an average target price of $24.86.

Xencor Trading Down 2.9%

XNCR opened at $28.44 on Thursday. Xencor, Inc. has a twelve month low of $7.80 and a twelve month high of $30.61. The firm has a market capitalization of $2.11 billion, a PE ratio of -13.11 and a beta of 0.85. The firm's 50-day moving average price is $19.21 and its 200 day moving average price is $14.57.

Xencor (NASDAQ:XNCR - Get Free Report) last released its quarterly earnings data on Wednesday, August 5th. The biopharmaceutical company reported ($0.29) EPS for the quarter, beating analysts' consensus estimates of ($0.80) by $0.51. Xencor had a negative net margin of 155.59% and a negative return on equity of 28.66%. The company had revenue of $51.22 million during the quarter, compared to the consensus estimate of $18.89 million. During the same quarter in the prior year, the firm earned ($0.41) EPS. Xencor's quarterly revenue was up 17.4% on a year-over-year basis. As a group, analysts predict that Xencor, Inc. will post -3 earnings per share for the current fiscal year.

Xencor Profile

Xencor, Inc is a clinical-stage biopharmaceutical company focused on the design and development of engineered protein therapeutics for the treatment of autoimmune diseases, cancer and neurological disorders. The company applies its proprietary XmAb® platform to manipulate antibody structure and function, creating molecules with enhanced immune engagement and extended half-life. Xencor's research programs span a range of therapeutic modalities, including monoclonal antibodies, bispecific antibodies and cytokine-based fusion proteins.

The XmAb® platform enables precise modification of the Fc region to augment key properties such as receptor binding, effector function and pharmacokinetics.

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest reporting and unbiased coverage. Please send any questions or comments about this story to contact@marketbeat.com.

Continue following MarketBeat

Add MarketBeat as your preferred source on Google to see our latest stories in your feed.

Add As Preferred Source